Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483555 | 1.00 | TACR1 (0.57) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4483547 | 1.00 | TACR1 (0.57) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4485766 | 0.93 | TACR1 (0.65) | TACR1 | |
| SCHEMBL4485768 | 0.93 | TACR1 (0.65) | TACR1 | |
| SCHEMBL4480800 | 0.93 | TACR1 (0.65) | TACR1 | |
| SCHEMBL4483142 | 0.90 | TACR1 (0.67) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4483149 | 0.90 | TACR1 (0.67) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4483139 | 0.90 | TACR1 (0.67) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4474037 | 0.90 | TACR1 (0.58) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4474027 | 0.90 | TACR1 (0.58) | TACR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | TACR1 6/4885CYP3A4 2319/4885CYP2D6 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.